AstraZeneca PLC (LON:AZN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of AstraZeneca PLC (LON:AZN) have received a consensus rating of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is £152.17.

A number of brokerages have recently commented on AZN. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and issued a £115 target price on shares of AstraZeneca in a report on Wednesday, September 2nd. Citigroup increased their price target on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Jefferies Financial Group restated a “buy” rating and issued a £175 price target on shares of AstraZeneca in a research report on Monday, August 3rd. Finally, Berenberg Bank reaffirmed a “buy” rating and set a £160 price objective on shares of AstraZeneca in a research note on Thursday, September 3rd.

AstraZeneca Trading Up 0.1%

Shares of LON AZN opened at £118.90 on Wednesday. The business’s 50 day moving average is £124.79 and its two-hundred day moving average is £136.10. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. AstraZeneca has a 1-year low of £107.84 and a 1-year high of £157.32. The stock has a market capitalization of £184.40 billion, a P/E ratio of 17.80, a PEG ratio of 0.86 and a beta of 0.20.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.